IDEXX(US:IDXX) ZACKS·2025-05-01 12:40Group 1 - Idexx Laboratories reported quarterly earnings of $2.96 per share, exceeding the Zacks Consensus Estimate of $2.92 per share, and showing an increase from $2.81 per share a year ago, representing an earnings surprise of 1.37% [1] - The company posted revenues of $998.43 million for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 1.77%, but an increase from $964.1 million year-over-year [2] - Idexx has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times during the same period [2] Group 2 - The stock has gained approximately 4.7% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current consensus EPS estimate for the upcoming quarter is $3.26 on revenues of $1.06 billion, and for the current fiscal year, it is $11.96 on revenues of $4.09 billion [7] - The Medical - Instruments industry, to which Idexx belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]